Antiplatelet Reversal and Bleeding

CE / CME

ISC 2025: Innovations and Expert Guidance in Antiplatelet Reversal and Bleeding Management 

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Released: February 18, 2025

Expiration: February 17, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following P2Y12 inhibitors act as a reversible inhibitor of platelet receptors?

2.

A person with a history of CAD presents to the ED with a sudden onset of headache, confusion, and right-sided weakness. A CT scan confirms an ICH requiring neurosurgery. The patient has been taking aspirin and clopidogrel for the past 6 mo following a PCI. Which of the following interventions is most appropriate at this time?

3.

A 72-yr-old person on ticagrelor presents with a spontaneous ICH. The neurologist considers bentracimab for antiplatelet reversal. According to the latest evidence, if approved and available, when should bentracimab be administered?